Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06348264
Status:
RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-03-30
Brief Title:
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive High-risk Salivary Duct Carcinoma
Sponsor:
Peking University First Hospital
Organization:
Peking University First Hospital
Organization Data
Organization:
Peking University First Hospital
Class:
OTHER
Study ID:
SDC-1
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking University First Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Beijing Biote Pharmaceutical CoLtd | UNKNOWN |
| Jiangsu Hengrui Pharmaceutical Co Ltd | INDUSTRY |